<DOC>
	<DOCNO>NCT01456052</DOCNO>
	<brief_summary>This multicenter , placebo-controlled , parallel-group , pilot study evaluate safety preliminary effectiveness two blind dose level LX1606 subject acute , mild moderate ulcerative colitis 5-aminosalicylic acid/mesalamine therapy .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy LX1606 Subjects With Acute , Mild Moderate Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Diagnosis ulcerative colitis least 6 month duration Disease extend least 15 cm proximally anal verge , document within past 3 year Flare occur 5aminosalicylic acid ( 5ASA ) /mesalamine therapy subject willing remain stable dose duration study Age â‰¥18 &lt; 70 year age Able willing provide write informed consent Prior terminal ileum colonic surgery , except appendectomy hemorrhoid surgery Presence indeterminate colitis , microscopic colitis , ischemic colitis , infectious colitis , clinical finding suggestive Crohn 's disease Clinical sign fulminant colitis toxic megacolon History dysplasia associate lesion mass ( DALM ) Subjects surgery ulcerative colitis , opinion investigator , likely require surgery ulcerative colitis study History primary sclerosing cholangitis Any physical laboratory abnormality deem investigator clinically significant Major surgery within 60 day Screening Use investigational agent within 30 day Screening therapeutic protein antibody within 90 day Screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>